
The global pharmaceutical industry continues to experience strong growth driven by innovation in biologics, oncology, diabetes and obesity treatment, vaccines, and rare disease therapies. In August 2026, Pharm Exec magazine published the 2026 Pharm Exec 50, ranking the Top 50 pharmaceutical companies worldwide by prescription drug (Rx) sales in fiscal year 2025.
This ranking is widely regarded as one of the most authoritative industry benchmarks, offering valuable insight for pharmaceutical manufacturers, API and packaging suppliers, pharmaceutical equipment companies, and distributors and contract manufacturing organizations (CMOs).
Below is the fully updated 2026 Global Top 50 Pharmaceutical Companies List, based on 2025 Rx sales.
目录
切换这个排名反映了 真实的商业表演, not market capitalization or valuation. Figures in the table are 2025 Rx sales, shown in US$ billion.
| 秩 | 公司 | 总部 | 2025 Rx sales (US$ billion) |
|---|---|---|---|
| 1 | 礼来公司 | 美国 | 60.78 |
| 2 | Johnson & Johnson | 美国 | 59.33 |
| 3 | 艾伯维 | 美国 | 58.27 |
| 4 | 罗氏公司 | 瑞士 | 57.51 |
| 5 | 阿斯利康 | 英国 | 55.04 |
| 6 | Merck & Co. (MSD) | 美国 | 54.69 |
| 7 | 诺华公司 | 瑞士 | 54.33 |
| 8 | 辉瑞公司 | 美国 | 49.91 |
| 9 | 赛诺菲 | 法国 | 48.97 |
| 10 | 百时美施贵宝 | 美国 | 47.75 |
| 11 | 诺和诺德 | 丹麦 | 46.80 |
| 12 | GSK (GlaxoSmithKline) | 英国 | 42.72 |
| 13 | 安进 | 美国 | 34.95 |
| 14 | 武田 | 日本 | 29.67 |
| 15 | 吉利德科学公司 | 美国 | 28.83 |
| 16 | 勃林格殷格翰 | 德国 | 23.82 |
| 17 | 拜耳 | 德国 | 19.19 |
| 18 | 中超联赛 | 澳大利亚 | 15.44 |
| 19 | 维亚特里斯 | 美国 | 14.09 |
| 20 | 梯瓦公司 | 以色列 | 14.08 |
| 21 | 安斯泰来 | 日本 | 12.60 |
| 22 | 第一三共 | 日本 | 12.04 |
| 23 | 福泰制药公司 | 美国 | 11.97 |
| 24 | 山德士集团 | 瑞士 | 11.09 |
| 25 | 大冢控股 | 日本 | 9.87 |
| 26 | 默克公司 | 德国 | 9.73 |
| 27 | 联合银行 | 比利时 | 8.24 |
| 28 | 格里福尔斯 | 西班牙 | 7.33 |
| 29 | 百健公司 | 美国 | 7.12 |
| 30 | 太阳制药 | 印度 | 6.44 |
| 31 | 再生元 | 美国 | 6.31 |
| 32 | 欧加农 | 美国 | 6.06 |
| 33 | 云南白药 | 中国 | 5.72 |
| 34 | 雅培 | 美国 | 5.51 |
| 35 | 施维雅 | 法国 | 5.44 |
| 36 | Bausch Health | 加拿大 | 5.41 |
| 37 | BeOne Medicines (formerly BeiGene) | 瑞士 | 5.28 |
| 38 | 费森尤斯 | 德国 | 5.21 |
| 39 | Shanghai Pharmaceuticals | 中国 | 5.16 |
| 40 | 卫材 | 日本 | 4.78 |
| 41 | Sino Biopharmaceutical | 香港 | 4.37 |
| 42 | 梅纳里尼 | 意大利 | 4.36 |
| 43 | 因塞特 | 美国 | 4.35 |
| 44 | 伊普森 | 法国 | 4.16 |
| 45 | argenx | 荷兰 | 4.15 |
| 46 | 爵士制药公司 | 爱尔兰 | 4.02 |
| 47 | STADA | 德国 | 4.02 |
| 48 | 华东医药 | 中国 | 3.97 |
| 49 | 江苏恒瑞医药 | 中国 | 3.85 |
| 50 | Haleon | 英国 | 3.60 |
Data source: Pharm Exec, 2026 Pharm Exec 50 (FY 2025 prescription drug sales). Company names use common English forms; BeOne Medicines appears under its current name (formerly BeiGene).
The headline change this year is Eli Lilly’s jump from No. 11 in the previous ranking to No. 1, with about $60.8 billion in 2025 Rx sales, up roughly 49% year over year. Johnson & Johnson, last year’s leader, is now No. 2. AbbVie, Roche, and AstraZeneca complete the top five.
Fifteen companies in the Top 50 are headquartered in the United States, still the largest national group, with particular strength in oncology, immunology, biologics, and metabolic disease, including GLP-1 therapies.
Switzerland is represented by Roche, Novartis, Sandoz, and BeOne Medicines (formerly BeiGene, now listed with a Swiss headquarters). Japan remains well represented by Takeda, Astellas, Daiichi Sankyo, Otsuka, and Eisai. Germany includes Boehringer Ingelheim, Bayer, Merck KGaA, Fresenius, and STADA.
Five Chinese companies are in this year’s list if Sino Biopharmaceutical (Hong Kong) is included: Yunnan Baiyao, Shanghai Pharmaceuticals (a new entrant), Sino Biopharmaceutical, Huadong Medicine, and Jiangsu Hengrui Medicine. CSPC Pharmaceutical Group is no longer in the Top 50. From India, Sun Pharma remains on the list; Dr. Reddy’s Laboratories is not in this year’s Top 50. New global entrants also include argenx (Netherlands) and Haleon (UK).
If you are involved in pharmaceutical machinery manufacturing, packaging solutions (vials, bottles, blister, ampoules), API and excipient supply, or contract manufacturing (CDMO/CMO), this list directly reflects where purchasing power is concentrated, which companies control global drug production, and who your most valuable long-term customers may be.
Based on this ranking, the pharmaceutical industry will continue focusing on biologics and biosimilars, GLP-1 diabetes and obesity drugs, cancer immunotherapy, rare disease treatments, and personalized medicine. Companies at the top of the 2026 Pharm Exec 50 are expected to drive mergers and acquisitions, equipment upgrades, and new plant investments worldwide.
此排名中的大多数公司都与生物制剂一起开展大型口服固体制剂 (OSD) 业务。他们的片剂和胶囊工厂围绕类似的工艺链建造,每个步骤都需要生产可重复批次的 GMP 级设备。我们详细介绍了这一点 全球50强制药公司使用哪些设备来保证质量.
| 工艺步骤 | 目的 | 建派相关设备 |
|---|---|---|
| 湿润的颗粒 | 使粉末致密化并提高流动性和含量均匀性 | 高剪切混合造粒机 (JHZ-C, JHZ-D) |
| 烘干 | 将颗粒水分降低至验证水平 | 流化床干燥机 (JFG-C型) |
| 定径和铣削 | 混合前控制颗粒大小 | 制药厂 (JZL分级造粒机) |
| 混合 | 将颗粒与润滑剂和赋形剂混合 | 制药搅拌机 (JPH三偏心搅拌机) |
| 涂层 | 片剂的薄膜、糖衣或肠溶衣 | 片剂包衣机 (JGB-D, JGB-E) |
| 综合线 | 封闭式、相连的造粒生产线可减少人工操作 | 全封闭造粒生产线, 连续制造 |
为这些领先者供货或与之竞争的仿制药和合同制造商通常会根据相同的标准来衡量自己的产品线。有关预算规划,请参阅我们的 片剂包衣机价格指南.
这 2026 Global Top 50 Pharmaceutical Companies Ranking provides a clear overview of the world’s leading drug manufacturers, based on 2025 prescription drug sales, and reflects the direction of the global pharmaceutical industry. From biologics and oncology to diabetes, obesity, and rare disease therapies, these top companies will continue to drive innovation, capacity expansion, and equipment upgrades worldwide.
作为专业的制药机械制造商, 江 closely follows the development trends of these global pharma leaders and is committed to providing reliable, high-efficiency production and processing solutions for pharmaceutical manufacturers across the world. Whether you are planning a new production line, upgrading existing equipment, or expanding your formulation and packaging capacity, JIANPAI offers customized solutions to meet your exact needs.
Eli Lilly is No. 1 in the 2026 Pharm Exec 50, with about $60.8 billion in 2025 prescription (Rx) drug sales. Johnson & Johnson is No. 2. The complete Top 50 table above ranks companies by 2025 Rx sales, as described in the methodology section.
Large OSD plants typically run high shear wet granulation, fluid bed drying, milling and sizing, blending, tablet compression, and film or functional coating, often with closed material transfer and automated cleaning.
Top companies set the quality and compliance expectations that generic and contract manufacturers follow. Equipment that meets their GMP, data integrity and containment needs is increasingly expected across the industry.
健派为口服固体制剂工厂提供制粒、干燥、研磨、混合和包衣设备。将您的产品和目标产能发送给我们以获取生产线提案。
电子邮件: [email protected] | 电话: +86 577-86932456 |中国浙江省温州市瓯江口新区菱德路989号